XNCR flags strategic shift to proprietary late-stage XmAb RCC development
Company discussion points to a strategic shift toward late-stage development of proprietary XmAb molecules, citing pivotal RCC data for an ENPP3 T-cell engager and expected ESMO timing.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.